In this first-in-human study, we evaluate the safety and dosimetry of 89 Zr-pertuzumab
PET/CT for HER2-targeted imaging in patients with HER2-postive breast cancer. Materials …

In what we believe to be a first-in-human study, we evaluated the safety and dosimetry of
89Zr-pertuzumab PET/CT for human epidermal growth factor receptor 2 (HER2)–targeted …

Radioimmunoconjugates targeting human epidermal growth factor receptor 2 (HER2) have
shown potential to noninvasively visualize HER2-positive tumors. However, the stochastic …

Purpose To determine if imaging with 89 Zr-trastuzumab, a human epidermal growth factor
receptor 2 (HER2)-targeting PET tracer can detect HER2-positive metastases in patients …

Women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer are
candidates for treatment with the anti-HER2 antibody trastuzumab. Assessment of HER2 …

Our objective was to determine whether imaging with a human epidermal growth factor
receptor 2 (HER2)–targeted PET tracer can detect HER2-positive metastases in patients …

1045 Background: Non-invasive diagnostic tools can optimize and evaluate HER2 directed
therapy in HER2 positive breast cancer patients. HER2 imaging with 111In-trastuzumab …

The anti–human epidermal growth factor receptor 2 (HER2/neu) antibody trastuzumab is
administered to patients with HER2/neu-overexpressing breast cancer. Whole-body …

The purpose of this study was to determine the safety, distribution, internal dosimetry, and
initial human epidermal growth factor receptor 2 (HER2)–positive tumor images of 64Cu …

Background Human epidermal growth factor receptor 2 (HER2)-targeted therapies are
successful in patients with HER2-positive malignancies; however, spatial and temporal …